Analyst Price Targets — AKBA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 6, 2026 11:51 am | Allison Bratzel | Piper Sandler | $4.00 | $1.38 | TheFly | Akebia price target lowered to $4 from $6 at Piper Sandler |
| March 28, 2024 12:08 pm | Ed Arce | H.C. Wainwright | $6.00 | $1.98 | TheFly | Akebia price target raised to $6 from $5 at H.C. Wainwright |
| March 3, 2022 12:00 am | Serge Belanger | Needham | $7.00 | $2.65 | Pulse 2.0 | Akebia Therapeutics (AKBA) Stock: $7 Price Target And Buy Rating |
Latest News for AKBA
Ionis Pharmaceuticals (NASDAQ: IONS - Get Free Report) and Akebia Therapeutics (NASDAQ: AKBA - Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, profitability, risk, earnings and dividends. Volatility and Risk Ionis Pharmaceuticals has a beta
CAMBRIDGE, Mass., April 13, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the first participants have been dosed in a Phase 1 clinical trial of AKB-9090, an internally developed hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor being evaluated for the treatment…
CAMBRIDGE, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P.
JPMorgan Chase and Co. lessened its holdings in Akebia Therapeutics, Inc. (NASDAQ: AKBA) by 39.8% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 994,181 shares of the biopharmaceutical company's stock after selling 658,565 shares during the quarter. JPMorgan Chase and Co. owned
Akebia Therapeutics (NASDAQ: AKBA) used its R&D Day presentation to outline a strategy centered on expanding its commercial anemia franchise while advancing three kidney disease pipeline programs: praliciguat in focal segmental glomerulosclerosis (FSGS), the tissue-targeted complement inhibitor AKB-097 (abribafisp) in complement-mediated kidney diseases, and AKB-9090 in cardiac surgery-associated acute kidney injury…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for AKBA.
U.S. House Trading
No House trades found for AKBA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.